Mill Creek
Mill Creek
Mill Creek, Washington, United States27 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06855498 | |
| Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Active, not recruiting | Not stated | 2026-10-06 | NCT06531109 | |
| A Study Evaluating APG777 in Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT06395948 | |
| This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Not stated | 2026-09-29 | NCT07290803 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06143878 | |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06095115 | |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06934226 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06095102 | |
| A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-09-23 | NCT07003425 | |
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | Plaque Psoriasis | Recruiting | Phase 3 | 2026-09-22 | NCT07116967 | |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | NonSegmental Vitiligo | Recruiting | Phase 3 | 2026-09-14 | NCT06548360 | |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis | Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Diseases, Papulosquamous, Skin Manifestations, Skin and Connective Tissue Diseases, exanthem, psoriasis, skin disorder | Recruiting | Phase 3 | 2026-09-03 | NCT06979453 | |
| A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 3 | 2026-09-02 | NCT06468228 | |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 3 | 2026-08-27 | NCT06241118 | |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 3 | 2026-08-20 | NCT05889182 | |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 3 | 2026-08-19 | NCT06832618 | |
| Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, androgenetic alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Active, not recruiting | Phase 3 | 2026-08-17 | NCT07146022 | |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Not yet recruiting | Phase 2 | 2026-08-14 | NCT07766005 | |
| Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Recruiting | Phase 2 | 2026-08-10 | NCT07474792 | |
| Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, cardiovascular disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Not applicable | 2026-08-06 | NCT05908240 | |
| A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris | Lichenoid Eruptions, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, lichen planopilaris, lichen planus, skin disorder | Recruiting | Phase 2 / Phase 3 | 2026-07-08 | NCT07532603 | |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense | Acneiform Eruptions, Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, acne, bacterial infectious disease, dermatitis, hidradenitis, hidradenitis suppurativa, sebaceous gland disorder, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 2 | 2026-06-30 | NCT06993610 | |
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Enrolling by invitation | Phase 3 | 2026-06-08 | NCT07007637 | |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | prurigo nodularis | Active, not recruiting | Phase 3 | 2026-05-28 | NCT06516952 | |
| Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Active, not recruiting | Phase 3 | 2026-04-13 | NCT06846541 |